SC
MLYS icon

Steven Cohen’s Mineralys Therapeutics MLYS Stock Holding History

Steven Cohen’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,911,433
Closed -$51.8M – 4379
2026
Q1 		$51.8M Buy
1,911,433
+704,213
+58% +$20.7M 0.07% 353
2025
Q4 		$43.8M Sell
1,207,220
-592,408
-33% -$23.8M 0.05% 468
2025
Q3 		$68.2M Buy
+1,799,628
New +$38.9M 0.11% 199
2024
Q2 		– Sell
-47,800
Closed -$617K – 2226
2024
Q1 		$617K Sell
47,800
-82,100
-63% -$1.01M ﹤0.01% 1590
2023
Q4 		$1.12M Sell
129,900
-33,285
-20% -$261K ﹤0.01% 1372
2023
Q3 		$1.55M Buy
163,185
+124,185
+318% +$1.62M ﹤0.01% 1205
2023
Q2 		$665K Buy
39,000
+34,000
+680% +$508K ﹤0.01% 1207
2023
Q1 		$78.3K Buy
+5,000
New +$84.2K ﹤0.01% 1684

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steven Cohen's MLYS Position: Q2 2026 in Review

Steven Cohen sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 1,911,433 shares — an estimated $51.8M sold.

Steven Cohen first reported a position in MLYS in Q1 2023 and held it in 8 quarters. The position peaked at $68.2M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Steven Cohen reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 1,911,433 Mineralys Therapeutics shares in Q2 2026, an estimated $51.8M.
  • Steven Cohen first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 8 quarters.
  • Steven Cohen's Mineralys Therapeutics position peaked at $68.2M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.